title: Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports.
abstract: BACKGROUND
  We assessed suicide and suicide attempt risk as well as symptom reduction among 3,282 depressed patients participating in duloxetine and escitalopram clinical trials assigned to either an antidepressant or placebo.
  
  
  METHODS
  We reviewed the FDA Summary Basis of Approval reports for data regarding safety and efficacy for duloxetine and escitalopram. Furthermore, we compared suicide risk among antidepressant clinical trials in this study with our two previous analyses on seven antidepressant clinical trials.
  
  
  RESULTS
  Suicide and suicide attempt risk varied considerably among the three analyses, showing up to ten fold differences. Interestingly, the variability exists across the three reports, rather than between treatments (antidepressants versus placebo).
  
  
  CONCLUSIONS
  These findings suggest caution in generalizing suicide risk even from a relatively large number of participants and thus, firm conclusions can only be drawn if the number of participants is overwhelmingly large (approximately two million patients). We also noted similar magnitude of response to placebo and antidepressants among the three studies.
authors: Northwest Clinical Research Center, Bellevue, WA, USA. akhan@nwcrc.net
authors: Arif
authors: A
authors: Khan
authors: Kelly
authors: K
authors: Schwartz
mesh_terms: D000704:Analysis of Variance; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D000068736:Duloxetine Hydrochloride; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D010555:Personality Inventory / Q000706:statistics & numerical data; D015990:Placebo Effect; D011594:Psychometrics; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018570:Risk Assessment / Q000706:statistics & numerical data; D013405:Suicide / Q000523:psychology / Q000706:statistics & numerical data; D013406:Suicide, Attempted / Q000517:prevention & control* / Q000523:psychology / Q000706:statistics & numerical data; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D000092864:Suicide Prevention
chemical_list: D013876:Thiophenes; D005473:Fluoxetine; D015283:Citalopram; D017374:Paroxetine; D000068736:Duloxetine Hydrochloride